Education and Training
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
Stanford is currently accepting patients for this trial.
Intervention(s):
- drug: BDC-1001
- drug: Nivolumab
Eligibility
Key Inclusion Criteria:
- Patient must have an advanced solid tumor with documented HER2-protein expression or
gene amplification for which approved therapies have been exhausted or are not
clinically indicated.
- Measurable disease as determined by RECIST v.1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Tumor tissue (archival or collected prior to the study start) available for
exploratory biomarker evaluation.
Key Exclusion Criteria:
- History of severe hypersensitivity to any ingredient of the study drug(s), including
trastuzumab or other monoclonal antibody.
- Previous treatment with a TLR 7, TLR 8 or a TLR 7/8 agonist.
- Impaired cardiac function or history of clinically significant cardiac disease
- Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or
hepatitis C infection.
- Active SARS-CoV-2 infection
- Untreated central nervous system (CNS), epidural tumor or metastasis, or brain
metastasis.
Other protocol defined inclusion/exclusion criteria may apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Anastasia L Harper
650-725-0378
I'm interested